Cargando…
Donafenib and GSK‐J4 Synergistically Induce Ferroptosis in Liver Cancer by Upregulating HMOX1 Expression
Hepatocellular carcinoma (HCC) is one of the most lethal cancers worldwide. Donafenib is a multi‐receptor tyrosine kinase inhibitor approved for the treatment of patients with advanced HCC, but its clinical effect is very limited. Here, through integrated screening of a small‐molecule inhibitor libr...
Autores principales: | Zheng, Chenyang, Zhang, Bo, Li, Yunyun, Liu, Kejia, Wei, Wei, Liang, Shuhang, Guo, Hongrui, Ma, Kun, Liu, Yao, Wang, Jiabei, Liu, Lianxin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10401117/ https://www.ncbi.nlm.nih.gov/pubmed/37330650 http://dx.doi.org/10.1002/advs.202206798 |
Ejemplares similares
-
Honokiol Induces Ferroptosis by Upregulating HMOX1 in Acute Myeloid Leukemia Cells
por: Lai, Xingrong, et al.
Publicado: (2022) -
Isoliquiritigenin induces HMOX1 and GPX4-mediated ferroptosis in gallbladder cancer cells
por: Wang, Zeyu, et al.
Publicado: (2023) -
Zoledronic acid induces ferroptosis by reducing ubiquinone and promoting HMOX1 expression in osteosarcoma cells
por: Ren, Tianhao, et al.
Publicado: (2023) -
Identification of HMOX1 as a Critical Ferroptosis-Related Gene in Atherosclerosis
por: Wu, Daiqian, et al.
Publicado: (2022) -
Donafenib treatment for hepatocellular carcinoma: A case report
por: Li, Qiaoqi, et al.
Publicado: (2021)